Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.53 |
| ▸ | EGFR | P00533 | 5/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.44 |
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | AGXT | P21549 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28327836 | 0.89 | TAAR1 (0.50) | TAAR1EGFRERBB2IDO1AGXT | |
| SCHEMBL1371390 | 0.85 | TAAR1 (0.57) | TAAR1EGFRERBB2IDO1AGXT | |
| SCHEMBL10296023 | 0.82 | TAAR1 (0.48) | TAAR1EGFRERBB2IDO1AGXT | |
| SCHEMBL12493473 | 0.81 | TAAR1 (0.58) | TAAR1EGFRERBB2IDO1AGXT | |
| SCHEMBL23703162 | 0.81 | TAAR1 (0.53) | TAAR1EGFRERBB2IDO1AGXT | |
| Hydrochloric Acid SCHEMBL27989720 | 0.81 | IDO1 (0.48) | TAAR1EGFRERBB2IDO1AGXT | |
| SCHEMBL2935743 | 0.81 | TAAR1 (0.47) | TAAR1EGFRERBB2IDO1AGXT | |
| SCHEMBL3255075 | 0.79 | TAAR1 (0.55) | TAAR1CNR1 | |
| SCHEMBL9477879 | 0.79 | MGLL (0.58) | TAAR1IDO1CA1CA2CA9 | |
| SCHEMBL23733099 | 0.79 | TAAR1 (0.50) | TAAR1EGFRERBB2IDO1AGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7462614-B2 | Imidazotriazine compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-09 | — | — | US | disclosed |
| US-20060217382-A1 | 7-(2-Bromophenyl)-5-methyl-N-(3,4,5-trimethoxyphenyl)imidazo[5,1-f][1,2,4]triazin-2-amine; to treat neoplasms; polo like kinases inhibitors; antineoplastic/antiproliferative agents; cyclization of 1,2,4-triazine derivatives; coupling if imidazo[5,1-f][1,2,4]triazines with amine or halogen derivatives | SMITHKLINE BEECHAM CORPORATION | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217382-A1 | 7-(2-Bromophenyl)-5-methyl-N-(3,4,5-trimethoxyphenyl)imidazo[5,1-f][1,2,4]triazin-2-amine; to treat neoplasms; polo like kinases inhibitors; antineoplastic/antiproliferative agents; cyclization of 1,2,4-triazine derivatives; coupling if imidazo[5,1-f][1,2,4]triazines with amine or halogen derivatives | PLK2, PLK1, CDKL5 | TAAR1 2160/4885EGFR 575/4885ERBB2 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.